Bacterial DnaK reduces the activity of anti-cancer drugs cisplatin and 5FU

20245 citationsJournal Articlegold Open Access

Authors

Francesca Benedetti · University of Maryland, Baltimore

Emmanuel F. Mongodin · University of Maryland, Baltimore

Jonathan H. Badger · United States Department of Health and Human Services

Arshi Munawwar · University of Maryland, Baltimore

Ashley Cellini · University of Maryland, Baltimore

Weirong Yuan · University of Maryland, Baltimore

Giovannino Silvestri

Abstract

Our findings offer a practical framework for designing and implementing novel personalized anti-cancer strategies by targeting specific bacterial DnaKs in patients with poor response to chemotherapy, underscoring the potential for microbiome-based personalized cancer therapies.

Topics & Keywords

Cancer Research and Treatments Bacteriophages and microbial interactions Gut microbiota and health

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Translational Medicine

Volume 22, Issue 1, pp. 269-269

DOI: 10.1186/s12967-024-05078-x

Field-Weighted Citation Impact: 1.97